i-SENS, Inc. (KOSDAQ:099190)
16,190
-310 (-1.88%)
Nov 7, 2025, 3:30 PM KST
i-SENS Revenue
i-SENS had revenue of 76.79B KRW in the quarter ending June 30, 2025, with 9.86% growth. This brings the company's revenue in the last twelve months to 305.89B, up 9.14% year-over-year. In the year 2024, i-SENS had annual revenue of 291.14B with 9.81% growth.
Revenue (ttm)
305.89B
Revenue Growth
+9.14%
P/S Ratio
1.46
Revenue / Employee
344.86M
Employees
887
Market Cap
446.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 291.14B | 26.02B | 9.81% |
| Dec 31, 2023 | 265.12B | 283.13M | 0.11% |
| Dec 31, 2022 | 264.84B | 31.90B | 13.70% |
| Dec 31, 2021 | 232.93B | 29.23B | 14.35% |
| Dec 31, 2020 | 203.71B | 13.86B | 7.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |